15 March 2011, Basle, Switzerland: Lumavita announced today that LMV-601 was authorized by German regulatory authorities to enter into Phase I on healthy human volunteers. LMV-601 is a first -in-class small molecule that has shown outstanding preclinical efficacy against the human papilloma virus (HPV). High risk HPV strains are responsible for the occurrence of almost all cervical cancers, and it is hoped to prevent such cancers by eradicating at an early pre-cancer stage the virus in infected women.